Tell us where the case stands

This intake is used for every satri-cel, CT041 and CLDN18.2 question submitted to Vialen. It does not determine treatment eligibility. It determines whether a case is ready for a structured clinical review.

I am

Contact Name

Phone (optional)

Patient Country

U.S. State (if applicable)

Diagnosis

Is the disease currently unresectable, recurrent or metastatic?

Number of Prior Systemic Treatment Lines

Has the Most Recent Treatment Stopped Working or Been Documented as Progression?

Month of Most Recent Progression (if known)

HER2 Result

CLDN18.2 Status

CLDN18.2 Positive-Tumor-Cell Percentage, if Known

CLDN18.2 Percentage Range (if exact number not known)

CLDN18.2 Staining Intensity

Current Setting

If Clinically Appropriate, Would International Travel Be Possible?

Is a U.S. Clinical Trial Currently Being Actively Discussed with the Treating Team?

If Medically Appropriate, Would the Family Consider Self-Pay Cross-Border Treatment?

Treating Oncologist / Institution (optional)

Preferred Contact Method

Please do not attach or email medical records, images or files through this form. Vialen will provide secure record-transfer instructions after initial screening.

This form does not determine medical eligibility for satri-cel, CT041 or any treatment. Clinical eligibility is determined only by a licensed treating clinical team.

I consent to be contacted by Vialen regarding this access question.

WHAT HAPPENS NEXT

Every submission is reviewed against the same three checks before Vialen proposes a next step.

CLINICAL SCREENING

Vialen reviews the disease state, biomarker information and treatment history you provide against the current satri-cel pivotal criteria.

LOCAL-OPTION CHECK

Before any China pathway is discussed, Vialen confirms whether a clearly preferable feasible U.S. standard treatment or open trial remains available.

STRUCTURED FOLLOW-UP

If the case is ready for deeper review, Vialen requests the specific records needed and moves the case toward formal clinical evaluation with a treating team.